An Efficacy and Safety Study of Palovarotene for the Treatment of MO

Stopped Trial was terminated early to analyze the accumulated data and evaluate the efficacy, safety and future of palovarotene in MO.

Conditions

• Exostoses, Multiple Hereditary

Interventions

• DRUG: Palovarotene 2.5 mg
• DRUG: Palovarotene 5.0 mg
• OTHER: Placebo

Sponsor

Clementia Pharmaceuticals Inc.